6 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 5 Phase 3, 2 Phase 1, 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 2, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Chikungunya Virus: new trials by email Literature Review of Chikungunya Virus trials Research Report on Chikungunya Virus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study of PepGNP-ChikV in Healthy Volunteers PepGNP-ChikV, Placebo - Chikungunya, Chikungunya Fever | Early Phase 1 | Not yet recruiting | Gylden Pharma Ltd | 40 | 2026-08-03 | 2026-04-29 |
| An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults CHIKV VLP vaccine, Placebo - Chikungunya Virus | Phase 3 | Recruiting | Bavarian Nordic | 6144 | 2026-05-26 | 2026-06-29 |
| A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children. CHIKV VLP vaccine, Placebo - Chikungunya Virus | Phase 3 | Active not recruiting | Bavarian Nordic | 720 | 2025-06-05 | 2026-09-30 |
| Trial of an Inactivated Chikungunya Virus Vaccine HydroVax-005 CHIKV, Placebo - Chikungunya Fever, Chikungunya Virus | Phase 1 | Completed | Najit Technologies, Inc. | 48 | 2024-11-04 | 2026-03-19 |
| Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years CHIKV VLP/adjuvant, Placebo - Chikungunya Virus | Phase 3 | Completed | Bavarian Nordic | 413 | 2022-05-12 | 2024-12-13 |
| A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine CHIKV VLP, adjuvanted - Chikungunya Virus | Phase 2 | Completed | Bavarian Nordic | 25 | 2021-10-11 | 2023-07-03 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine) CHIKV VLP/adjuvant, Placebo - Chikungunya Virus | Phase 3 | Completed | Bavarian Nordic | 3258 | 2021-09-29 | 2024-08-30 |
| Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants VAL-181388, Placebo - Chikungunya Virus | Phase 1 | Completed | ModernaTX, Inc. | 60 | 2017-07-19 | 2024-06-10 |
| A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components INTERCEPT Platelets - Chikungunya Virus, Dengue Virus | Completed | Cerus Corporation | 90 | 2015-03-01 | 2018-10-30 | |
| CuraChik : A Trial of the Efficacy and Safety of Chloroquine as Therapeutic Treatment of Chikungunya Disease Chloroquine - Chikungunya Virus | Phase 3 | Terminated | Assistance Publique Hopitaux De Marseille | 2006-05-01 | 2015-08-28 |
Chikungunya Fever (7) · Communicable Diseases (1)
Alphavirus Infections (7) · Arbovirus Infections (7) · Infections (7) · Mosquito-Borne Diseases (7) · RNA Virus Infections (7) · Togaviridae Infections (7) · Vector Borne Diseases (7) · Virus Diseases (7) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Chloroquine (1)
Bavarian Nordic (5) · Assistance Publique Hopitaux De Marseille (1) · Cerus Corporation (1) · Gylden Pharma Ltd (1) · ModernaTX, Inc. (1) · Najit Technologies, Inc. (1)
United States (6) · Philippines (2) · Puerto Rico (2) · France (1) · Thailand (1)
Patrick Ajiboye, MD (3) · Patrick Ajiboye (1) · Susan L Stramer, PhD (1) · Xavier de Lamballerie, MD (1)
PMID 35709798, PMID 37210308, PMID 39004524, PMID 40158524, PMID 40158526
U44AI152995 (1)